Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.25M | $8.27M | $15.4M | $18.2M | $29.5M | $41.4M | $58.5M | $69.3M | $80.3M |
| Revenue growth | — | 94.9% | 86.7% | 17.9% | 61.8% | 40.6% | 41.1% | 18.6% | 15.8% |
| Gross profit | $2.53M | $2.94M | $9.27M | $11.2M | $18.8M | $27.0M | $40.1M | $46.5M | $54.3M |
| Gross margin | 59.6% | 35.6% | 60.0% | 61.7% | 63.9% | 65.3% | 68.6% | 67.1% | 67.7% |
| Operating income | -$16.9M | -$17.8M | -$19.2M | -$25.3M | -$29.5M | -$39.0M | -$44.1M | -$34.1M | -$33.8M |
| Operating margin | -398.7% | -214.9% | -124.1% | -138.8% | -100.0% | -94.2% | -75.4% | -49.2% | -42.0% |
| Net income | -$21.3M | -$21.1M | -$22.4M | -$28.8M | -$33.3M | -$44.3M | -$46.7M | -$37.8M | -$38.8M |
| Net margin | -502.6% | -254.9% | -145.2% | -158.1% | -112.9% | -106.9% | -79.8% | -54.6% | -48.4% |
| EPS (diluted) | — | -$101.41 | -$17.10 | -$2.23 | -$2.30 | -$2.72 | -$2.04 | -$1.33 | -$0.83 |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$16.4M | -$19.9M | -$25.5M | -$24.5M | -$30.4M | -$40.7M | -$40.9M | -$41.6M | -$28.2M |
| Capital expenditures | $114K | $62.0K | $197K | $167K | $627K | $872K | $611K | $989K | $448K |
| Free cash flow | -$16.5M | -$20.0M | -$25.7M | -$24.6M | -$31.1M | -$41.6M | -$41.5M | -$42.6M | -$28.7M |
| Fiscal year | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $11.3M | $17.3M | $45.3M | $74.4M | $43.9M | $42.0M | $46.7M | $52.7M | $50.8M |
| Total assets | — | $27.2M | $67.9M | $86.5M | $62.5M | $67.9M | $78.0M | $86.6M | $81.4M |
| Total liabilities | — | $40.9M | $37.0M | $37.4M | $42.4M | $53.5M | $59.2M | $58.1M | $75.1M |
| Long-term debt | — | — | $30.2M | $30.8M | $31.5M | $39.9M | $40.5M | $41.1M | $55.7M |
| Shareholders' equity | -$108M | -$138M | $31.0M | $49.0M | $20.1M | $14.3M | $18.9M | $28.5M | $6.31M |
| Retained earnings | — | -$138M | -$168M | -$197M | -$230M | -$274M | -$321M | -$359M | -$398M |
| Shares (wtd avg diluted) | — | 296K | 1.77M | 12.9M | 14.5M | 16.3M | 22.9M | 28.5M | 46.9M |
Every figure is extracted from TELA Bio, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.